Fewer than 1% of UK Doctors Trained to Prescribe Medical Cannabis: Seven Years on, Patient Demand Outpaces Healthcare Education
Seven years after medical cannabis was legalised in the UK, the sector stands at a critical crossroads. Demand for cannabis-based medicinal products (CBMPs) continues to accelerate, yet the country’s medical infrastructure is struggling to adapt. Despite the progress, less than 1% of the UK’s 100,000 doctors registered on the General Medical Council (GMC) Specialist Register possess the requisite training to prescribe medical cannabis, leaving tens of thousands of patients with limited access to treatments now available through private healthcare channels.
The regulatory approval of medical cannabis in November 2018 marked a pivotal moment for UK healthcare, promising relief for those with chronic pain, epilepsy, anxiety, and other qualifying conditions. However, the pathway from changing the law to delivering meaningful patient care has been fraught with systemic challenges. A rapidly expanding market, exemplified by a projected 80,000 patients receiving medical cannabis in 2025 and up to 190,000 by 2029, underlines persistent gaps in education, training, and clinical guidance across both public and private sectors.
Data Highlights: Market Growth Versus Clinical Training
Industry data reveals the stark contrast between surging patient numbers and the limited pool of qualified prescribers. Research conducted by Prohibition Partners suggests the UK will generate an estimated medical cannabis market value of €619 million (£539 million) by the end of the decade. Despite this financial growth, the number of clinicians effectively engaging with CBMPs remains comparatively static, with current estimates placing active medical cannabis prescribers at around 180—representing less than 1% of those authorised to prescribe.
A recent report from the All-Party Parliamentary Group (APPG) found that 3% to 4% of the UK population could potentially benefit from cannabis prescriptions. Nevertheless, the NHS has issued fewer than five medical cannabis prescriptions since legalisation, indicative of significant institutional hesitation, confusion, or lack of capacity. This contrasts sharply with patient demand tracked in the private sector, where clinics specialising in CBMPs have proliferated, often operating outside the framework of NHS guidance.
Barriers Inside the System: Education, Guidance, Infrastructure
“The lack of clinical education on cannabis medicine is the primary bottleneck,” stated Professor Mike Barnes, Chair of the Medical Cannabis Clinicians Society (MCCS). Universities in the UK have not made medical cannabis or CBMPs a formal part of the medical curriculum. This absence extends into postgraduate medical education, where no centralised or standardised training exists for the safe and effective use of CBMPs. Senior policy analysts and clinical educators argue that without robust education and state-sanctioned clinical protocols, clinicians remain hesitant to engage with medical cannabis therapy, fearing professional risk or patient safety concerns.
There is also no unified NHS guidance on CBMPs, which has led to considerable variance in practice between private providers and public hospitals. This lack of consistency has undermined both patient confidence and practitioner readiness. Leading healthcare economists suggest that this gap in training and clinical frameworks could stifle innovation and prevent optimal integration of cannabis medicines into broader treatment protocols. The result is a two-tiered system, with those able to afford private prescriptions accessing treatment, while others wait for NHS uptake to materialise.
International Context: Lessons from Abroad
The UK’s experience stands in contrast to approaches taken in other jurisdictions. For example, in countries such as Canada, Israel, and Germany, medical cannabis has been integrated into training programmes and clinical pathways after legalisation, with national regulatory bodies issuing explicit guidelines for prescribers. In Israel, the Ministry of Health oversees a structured educational programme, ensuring both patient safety and professional development. German physicians, following the Bundestag’s decision to legalise medical cannabis in 2017, have benefited from government-supported workshops, peer-reviewed guidelines, and dedicated research funding to study clinical efficacy. These countries demonstrate that the medical adoption of cannabis can be streamlined by prioritising education and evidence-based guidance.
Comparatively, the UK has taken a more cautious approach, influenced by historical stigma and the absence of long-term clinical data. The British Medical Association (BMA) and the Royal College of Physicians have issued conservative advisories, urging caution until substantive research on safety and efficacy emerges. Critics argue that this conservatism has stifled clinical confidence and contributed to the slow uptake among practitioners, while others maintain that high regulatory standards protect public safety.
Patient Impact: Chronic Conditions and Unmet Needs
For patients living with chronic pain, epilepsy, anxiety, or sleep disorders, legal access to CBMPs still feels theoretical. Advocacy groups estimate that hundreds of thousands of people may be eligible for medical cannabis prescriptions based on clinical need, but institutional inertia and lack of clinical training continue to be significant obstacles. According to the Medical Cannabis Clinicians Society, failure to provide comprehensive education deprives tens of thousands of candidates of a potentially beneficial therapy.
Tania Richards, a clinical psychologist experienced in pain management, observes, “The vast majority of eligible patients in the UK are unaware that medical cannabis is even a treatment option, and those who are aware often struggle to find a doctor willing or able to prescribe it.” Her experience reflects broader confusion in the healthcare community and among patients themselves.
The impact of limited access is especially marked among populations with refractory conditions—those who have not responded to mainstream therapies. In paediatric epilepsy and treatment-resistant chronic pain, international case studies have demonstrated measurable improvements after incorporating medical cannabis into care protocols, but replicating such outcomes in the UK will require meaningful shifts in education, legal clarity, and social perception.
Bridging the Gap: The Role of Professional Symposiums and Private Sector Initiatives
Recognising the urgent need to improve clinical knowledge, hundreds of healthcare professionals are set to attend the Cannabis Health Symposium in London on November 25, 2025. Organised in partnership with Curaleaf Laboratories and the MCCS, this event aims to deliver expert-led, clinically grounded education on cannabis medicine and CBMPs. Key sessions are expected to address safety, dosing, patient selection, and regulatory compliance, targeting clinicians who have yet to engage with medical cannabis practices.
Jonathan Hodgson, CEO of Curaleaf Laboratories, explained, “While the adoption of medical cannabis is still only in its infancy here in the UK, we want to help widen access for patients. For the medical community to adequately support patients, it’s essential they are able to access up-to-date education on cannabis-based medicines.” Symposium organisers believe that expanding clinical expertise and sharing evidence-based best practices will drive broader adoption and improve regulatory compliance.
The private sector has also been pivotal in education and supply chain developments. A growing number of specialist clinics offer training for clinicians, often supported by pharmaceutical partners with global experience in medical cannabis products. Such initiatives are designed to fill current gaps in NHS and university curricula.
Regulatory Oversight and Long-Term Policy Directions
Government agencies continue to debate how best to balance public safety with patient demand. The Home Office, which oversees drug scheduling, maintains strict oversight of cannabis distribution, requiring all CBMPs to meet rigorous standards. The GMC provides legal authorisation for specialist doctors to prescribe cannabis, but actual engagement depends on clinical training and personal initiative. The National Institute for Health and Care Excellence (NICE) has published limited guidelines, recommending CBMPs only in cases where traditional treatments have failed; critics argue these guidelines are overly restrictive and have contributed to the low rate of NHS prescriptions.
Healthcare policy analysts suggest that for sustained progress, the UK needs to invest in medical education, standardise clinical pathways, and encourage outcome-focused research. The integration of CBMPs into routine clinical practice requires not just legal access but also professional confidence, effective training, and continuous safety assessment.
Looking Ahead: Education as the Linchpin for Progress
The future of medical cannabis in the UK hinges on clinician education and the development of functional, evidence-led clinical protocols. While the market continues to grow and public interest expands, only a small fraction of authorised doctors are prescribing CBMPs. This gulf between demand and professional capacity serves as a warning: unless healthcare institutions prioritise education, research, and policy development, the promise of medical cannabis will remain unfulfilled for many patients.
The coming years offer an opportunity to align policy, education, and clinical practice. By adopting successful strategies from jurisdictions such as Canada and Germany, UK health authorities can ensure patient safety and access while promoting innovation. The Cannabis Health Symposium marks a step toward bridging existing gaps, but broad, systemic changes will be necessary to fully realise the potential of medical cannabis in British healthcare.
Medical cannabis in the UK stands at a pivotal moment. Institutional inertia and educational gaps have limited the impact of legalisation, but the willingness of clinicians, industry leaders, and policymakers to collaborate points towards a future where CBMPs can become a routine option in patient care. The next chapter will depend on sustained investment in education, evidence-led practice, and the alignment of market and regulatory priorities. Only by meeting these challenges can the UK unlock the full potential of medical cannabis for those who need it most.